In recent years, with the continuous advancement of medical technology, the survival of liver cancer patients has been significantly improved. Nowadays, with local liver cancer as the core, the combination of targeting and immunity has become an important means of transformation, bringing hope to many patients with advanced liver cancer.
In the process of advanced liver cancer patients, the system plays a vital role. Traditional** methods, such as surgery, chemotherapy and radiotherapy, are no longer sufficient to meet the needs of patients. As a result, researchers have set their sights on more advanced joint solutions. Combination refers to the organic combination of two or more methods in order to achieve better results.
Local ** is the core of the combined ** protocol, which mainly includes interventional, radiotherapy and ablation ** methods. Among them, interventional ** still has an irreplaceable position in liver cancer**. In particular, the use of TACE or HAIC this year, or TACE combined with HAIC, has achieved good results, but it can also be combined with other means, such as radiotherapy, ablation, etc., to shrink the tumor and give patients the opportunity to undergo surgery.
Targeting is a method that targets specific genes or protein molecules to precisely target tumor cells and reduce damage to normal tissues. In recent years, the development of targeting** has changed with each passing day, and many targeted drugs for liver cancer have appeared, such as sorafenib, lenvatinib, etc. These drugs have shown remarkable results in prolonging patient survival.
Immunity is a method that has developed rapidly in recent years to attack tumor cells by activating a patient's immune system. Similar to targeting, immunity also targets tumor cells with precision while reducing damage to normal tissues. Immunology has also made important breakthroughs in the field of liver cancer, and drugs such as immune checkpoint inhibitors have entered clinical application.
The key to the combination is the synergy between targeting and immunization. Studies have shown that the combination of targeted** and immune** can enhance efficacy and reduce*** For example, the combination of PD-1 PD-L1 inhibitors with anti-angiogenic drugs** has been shown to improve survival in liver cancer patients.
In short, the combination has become a new choice for patients with advanced liver cancer, bringing hope to many patients. In the future, with the further development of medical technology, it is believed that there will be more safe and effective combination solutions to provide more accurate choices for liver cancer patients.